Psoriatic arthritis flare; struggle to Oxygen levels above 94 percent for a while; Herniated disc; Fatigue; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4351418-00 (AbbVie).  A 36-year-old female patient received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (Batch/Lot number: unknown) at citrate free for psoriatic arthropathy. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1), for COVID-19 immunization; Covid-19 vaccine (DOSE 2; MANUFACTUERER UNKNOWN), for COVID-19 immunization. The following information was reported: PSORIATIC ARTHROPATHY (medically significant), outcome "recovering", described as "Psoriatic arthritis flare"; OXYGEN SATURATION DECREASED (non-serious), outcome "recovered", described as "struggle to Oxygen levels above 94 percent for a while"; INTERVERTEBRAL DISC PROTRUSION (non-serious), outcome "recovering", described as "Herniated disc"; FATIGUE (non-serious), outcome "not recovered". The patient underwent the following laboratory tests and procedures: Oxygen saturation: above 94. The action taken for adalimumab was unknown.  Clinical course: Solicited report from the by a consumer of an adult female with events of non-serious struggle to get oxygen levels above 94 percent for a while herniated disc, fatigue and psoriatic arthritis flare with Humira (Adalimumab). There was no reported medical history. On unknown dates the patient experienced struggle to get oxygen levels above 94 percent for a while herniated disc, fatigue and psoriatic arthritis flare. On an unknown date struggle to get oxygen levels above 94 percent for a while resolved. Pfizer bio-ntech Covid-19 vaccine (Tozinameran) was also considered suspect. It was unknown if patient was enrolled in a Covid-19 vaccine trial.  The reporter's assessment of the causal relationship of "psoriatic arthritis flare", "struggle to oxygen levels above 94 percent for a while", "herniated disc" and "fatigue" with the suspect product(s) BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  The reporter's causality for the event(s) of struggle to get oxygen levels above 94 percent for a while. and fatigue was not provided. the reporter's causality for the event(s) of herniated disc with Humira (Adalimumab) was no reasonable possibility. the reporter's causality for the event(s) of psoriatic arthritis flare with Humira (Adalimumab) was a reasonable possibility.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information in the case report, a possible causal relationship between reported events and suspect drug BNT162B2 cannot be excluded  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate